Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Amgen

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Novartis

Pfizer

Roche Holding AG

Sanofi

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

Big Pharma wages stealth war on drug price watchdog

Merck & Co., Inc. (MRK) Management Presents at CitiBank 15th Annual BioPharma Virtual Conference Transcript

Abbott Labs

According to the GuruFocus All-in-One Screener as of Sep. 10, the following healthcare stocks are popular among gurus.

5 Health Care Stocks in Gurus' Portfolios

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies

Amazon

Covetrus Inc

Nestle SA

Zoetis

Despite the economic challenges of the pandemic, Americans are spoiling their pets. Profit from that hot market with these top growth stocks.

5 Hot Growth Stocks to Buy With Fido in Mind

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference

Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference

"When you're putting these vaccines into healthy people, you have to do everything possible to ensure that these vaccines are both safe and effective," Merck Chief Executive Kenneth Frazier said. 

‘You can’t rush science’ — Merck CEO stresses need for careful approach to coronavirus vaccine

Pioneer Natural Resources

Vanguard Small Cap Value ETF

Vanguard S&P Small-Cap 600 ETF

Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.

Generation X Investors: Deja Vu?

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Merck Announces Detailed Data on Late-Stage Cough Candidate

AstraZeneca

BioNTech SE

Moderna

Novavax

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

WESTPORT, Conn.--(BUSINESS WIRE)-- #BMS--Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 studies

Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 Studies

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results from Two Phase 3 Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine

Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck’s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo in Patients with Refractory or Unexplained Chronic Cough

Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

Apple

Flushing Financial

Home Depot

JPMorgan Chase & Co

Coca-Cola

Bancorp

Week 37 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Citi 15th Annual BioPharma Virtual Conference

Merck to Present at the Citi 15th Annual BioPharma Virtual Conference

Disney

Intel

McDonald's

Altria

Procter & Gamble

Let’s face it – blue-chip stocks aren’t the most popular investments in the new normal. But look a little deeper and you’ll find a stalwart that will suit multiple investment strategies.

10 Blue-Chip Stocks Ideal for Any Investor

SPDR Dow Jones Industrial Average ETF

Invesco Dow Jones Industrial Average Dividend ETF

Dow Inc

The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.

Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care

New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care

After a 28% rise since the March 23 lows of this year, at the current price of around $85 per share we believe Merck’s stock looks attractive and it has more room for growth. MRK stock has moved from $66 to $85 off the recent bottom compared to the S&P which moved 55%, with the resumption of.

Should You Buy Merck Stock At $85?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

Chevron

Endeavour Silver

Kindred Biosciences

Verizon

Walmart

Two Sample Breakout Stocks for Week 36 with better than 10% short-term upside potential. Now up an average 183.6% YTD.

Week 36 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?

Bayer AG

Biogen

Philip Morris

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating).

Wide Moat Stocks On Sale - The September 2020 Heat Map

Bristol-Myers

Eli Lilly

If you had gone off the grid in early January with no communication and just came back, you would see all the market indexes making new highs, but the levels are close to when you left.

News for Merck Stock (MRK)